TORONTO and HOUSTON, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF),...
Data demonstrate potent suppression of MAPK signaling and viability in KRAS mutant cell lines, as well as anti-tumor activity across...
Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new...
NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Triomics, an oncology-focused generative AI company, today announced a collaboration through Memorial Sloan Kettering...
The Medical Device Market is witnessing robust expansion driven by rising healthcare expenditure, growing prevalence of chronic diseases, and accelerating...
In this free webinar, gain insight into enhanced efficiency and cost savings through automated processes like proposal development, feasibility analysis...
NAPLES, FL / ACCESS Newswire / October 23, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell...
With the industry's largest network of sites, Florence sets a new benchmark for AI-enabled study startup, workflow automation, and operational...
Combining peer-reviewed science, superior comfort, and thoughtful design, the Assisi Loop Lounge expands Zomedica's evidence-based therapeutic portfolio and reinforces Assisi's...
Consistency of BMD gains presented at NAMS 2025 demonstrate EB613’s efficacy in both young postmenopausal women and in women 10...
Significant milestones are approaching in drug development; additional digital asset purchases expected Preparation for FDA IND application expected to commence...
Biofrontera Inc. acquires full U.S. rights to Ameluz® and RhodoLED®, including New Drug Application and associated patents, from former parent...
Outstanding measure of efficacy relative to high-risk cancers with limited treatment options CHICAGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- MAIA...
"The ex-New Jersey Attorney General and former DEA Administrator promised to modernize justice through data. Instead, under her watch, illegal...
Company to discontinue development of mRNA-1647 in congenital CMVCompany will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in...
ROCKVILLE, MD / ACCESS Newswire / October 22, 2025 / Every generation has its frontier. For the last century, medicine's...
Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's...
SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"),...
CLEVELAND CLINIC ABU DHABI (CCAD) IS THE PRINCIPAL INVESTIGATOR IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PA / ACCESS Newswire /...
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET...